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Abstract The aim of our study is to investigate patient
selection for the 21-gene recurrence score assay (RS) for
breast cancer (BC) and the RS impact on chemotherapy
administration (Chemo) in clinical practice across the
United States through the retrospective observational study
of National Cancer Data Base (NCDB) patients from 2010
to 2012. NCDB captures *70 % of all newly diagnosed
malignancies in the USA annually. The 2010–2012 period
depicts data from the beginning of the NCDB that required
recording of molecular assays and their data release in
April 2015. De-identified demographic and clinical vari-
ables of patients that had RS results were analyzed.
513,080 patients had BC; 406,525 were estrogen receptor-
positive (ER?). 74,334/91,651 patients with RS recorded
as a numerical value (0–100) were analyzed (18.2 % of
ER?). Patients’ ages ranged from 18 to 90 (mean = 58.8,
median = 59); 99.1 % were females. Patients of Caucasian
race, from regions with\7 % having no high school edu-
cation, and[$63,000 median household income were more
likely to be tested than patients of other races, education, or
income (p\ 0.001). 58.1 % of tests were performed in
ER?/lymph node-negative/[1 cm tumors; 16.4 % inclu-
ded CN1 disease; 9.9 % included T1a, T3, Stage III and
IV, or HER2-positive cancers. Low-risk RS result had
92.2 % negative predictive value for no Chemo. Interme-
diate-risk RS result had 40.1 % positive predictive value
(PPV); high-risk RS had 81.2 % PPV for Chemo. RS is
obtained in *1/5 of ER ? BC patients across the USA.
Further studies investigating influence and implementation
of the newest evidence-based management guidelines
regarding patients’ selection for RS test and chemotherapy
administration upon obtaining of test results are warranted.
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Introduction
The 21-gene recurrence score (RS) assay for breast cancer,
commercially available since January 2005 (Oncotype DX,
Genomic Health Inc, Redwood City, CA), is designed for
use in early-stage estrogen receptor-positive (ER?), human
epidermal growth factor receptor-2 (HER2)-negative,
node-negative invasive breast cancers to predict disease
recurrence of tamoxifen-treated patients [1]. The test pro-
vides a low, intermediate, or high 10-year risk RS for
breast cancer [1]. Based on the score, the addition of
Part of this study was presented at the San Antonio Breast Cancer
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adjuvant chemotherapy to endocrine therapy is recom-
mended for high-risk RS, while no benefit is seen for low-
risk RS [2]; the benefits of adjuvant chemotherapy in
addition to endocrine therapy for intermediate-risk RS are
unclear [2].
The payment for Oncotype DX (OncoDX) test was
approved by the Centers for Medicare & Medicaid Services
(CMS) in 2006 [3]. Since 2010, the test has also been used
for ER?/HER2- and 1–3 lymph node-positive post-
menopausal women with breast cancer and provides low-,
intermediate-, and high-risk 5-year RS and mortality score
in these patients [4].
Since inception, patient selection for the OncoDX test has
been evolving, reaching the level of category 2A evidence in
the National Comprehensive Cancer Network (NCCN)
guidelines for breast cancer version 2.2015 [5]. The NCCN
panel suggested the OncoDX assay as ‘‘an option when
evaluating patients with primary tumors characterized as
0.6–1 cm with unfavorable features or [1 cm, and node-
negative, hormone receptor-positive, and HER2-negative’’.
However, the most recent version of the NCCN breast
cancer guidelines 1.2016 [6] as well as just published
American Society of Clinical Oncology (ASCO) Clinical
Practice Guideline [7] endorsed OncoDX assay as both a
prognostic and predictive test for breast cancer recurrence and
response to chemotherapy. This update coincided with Trial
Assigning Individualized Options for Treatment (TAILORx)
interim findings published in the New England Journal of
Medicine [8] which claimed prospective prognostic and
predictive validation of OncoDX assay. This trial, however,
utilized different cut-off values for the low-, intermediate-,
and high-risk RS from the commercial test values. Interest-
ingly though, the traditional commercial test cut-off values
are referenced by the newest NCCN guidelines [6].
Data on utilization and impact of the OncoDX breast
cancer assay in clinical practice so far are based on small
single or multi-institutional studies or meta-analysis [9–
13], as well as impact of the test in countries other than the
United States [14, 15]. Only a few recent publications
studied utilization and impact of the test in limited popu-
lation groups in the United States [16–19].
Since the data on appropriate utilization and impact of
the OncoDX assay in everyday clinical practice across the
entire United States population are still lacking, we
investigated the impact of the test across the United States
in a retrospective observational study of National Cancer
Data Base (NCDB) patients from 2010 to 2012. We
examined racial and socioeconomic factors in test utiliza-
tion, practices used for ordering the test, and the impact of
test results on adjuvant chemotherapy use. We also com-
pared chemotherapy utilization and vital status of patients
when applying commercial OncoDx cut-off values [2]
versus the new TAILORx trial-defined cut-off values [8].
Methods
National Cancer Data Base (NCDB) and study
approval
NCDB is a clinical oncology database, acquiring data from
hospital tumor registries, gathered from more than 1500
Commission on Cancer (CoC)-accredited facilities. NCDB,
jointly sponsored by the American College of Surgeons
(ACoS) and the American Cancer Society (ACS), currently
captures *70 % of all newly diagnosed malignancies in
the USA annually [20].
The 2010–2012 study period captures NCDB data from
the beginning of the NCDB required recording of molecular
assay test results in different types of cancers and the NCDB
data released in April 2015. For breast cancer, NCDB
captured data on genomic tests with only three separate
codes which identified ‘‘Oncotype DX test,’’ ‘‘MammaPrint
test,’’ and ‘‘Other’’ as separate tests. In 2010–2012 time
period, 97,510 genomic tests for breast cancer were cap-
tured by NCDB, with Oncotype DX test dominating by the
number of tests performed (91,651 tests = 94 %). Mam-
maPrint test was performed in 2518 cases (2.5 %), and other
tests, including the ones performed but of unknown type,
were done in 3341 patients (3.4 %).
Data regarding patients’ and institutions’ names were
de-identified by the NCDB prior to the release of the file
and therefore met the criteria of 45 CFR 46.102 d research.
Since the information received was not individually iden-
tifiable, the research was not a deemed research with
human subjects; therefore, our Institutional Review Board
was not required.
Patients’ selection
Demographic and clinicopathologic variables of patients
with OncoDX results expressed as a numerical value
(0–100) were analyzed. Those with performed OncoDX
assay but unknown numerical results were excluded.
Analysis
Tables 1 and 2 define the demographic, clinical, and
pathologic characteristics of this study population.
Chemotherapy administration (Table 3), recorded as
‘‘chemotherapy at any CoC facility’’ was used as a variable for
analysis of chemotherapy administration. Negative predictive
value for no chemotherapy administration for low-risk RS and
positive predictive value for chemotherapy administration for
intermediate- and high-risk RS were calculated.
Chemotherapy utilization and vital status of patients
tested with OncoDX (Table 4) were compared using
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traditional, commercial OncoDX cut-off values for low-,
intermediate-, and high-risk RS versus TAILORx trial new
cut-off values for the test.
Statistical analysis
Normality of continuous variables was assured using
skewness and kurtosis statistics. Any skewness or kurtosis
statistic above an absolute value of 2.0 was considered
normal. Levene’s Test of Equality of Variances was used to
test for homogeneity of variance in between-subjects
comparisons of continuous outcomes. Frequency statistics
were used to analyze categorical variables. Unadjusted odds
ratios with 95 % confidence intervals were used to test
associations with categorical outcomes. Logistic regression
was used to generate adjusted odds ratios with 95 % con-
fidence intervals. Residual analysis was conducted to assess
the model fit. Normality and homoscedasticity were also
assessed using plots of standardized residuals.
Statistical significance was assumed at an alpha value of
0.05, and all analyses were conducted using SPSS Version
23 (Armonk, NY; IBM Corp).
Results
The NCDB registered 513,080 patients with invasive breast
carcinoma from 1/1/2010 to 12/31/2012 with 406,525
patients recorded as ER-positive. Of note, the NCDB records
ER assay results from pathology reports or separate clinical
laboratory report sources based on reported immunohisto-
chemical results or much less frequently based on the
amount of cytosol protein in the tumor sample measured in
femtomoles of cytosol protein per milligram (fmol/mg) and
not based on mRNA results from Genomic Health. However,
there is no way to know which test was used by NCDB for
reported ER results available for our analysis.
The OncoDX test was performed in 91,651 patients;
86,409 patients had known OncoDX results, and 74,334
patients had tests recorded as a numerical value from 0 to
100.
Ages ranged from 18 to 90; 99.1 % were females. Per-
cent of breast cancer patients per age group was similar for
low-, intermediate-, and high-risk score in patients
41–70 years old, but there was an increasing trend toward
high-risk score in patients younger than 40 and older than
70 years of age. While this was expected in younger
patients, it was unexpected in elderly patients (Fig. 1).
Race and socioeconomic disparity analysis showed that
patients of Caucasian race, from regions with\7 % having
no high school education, and[$63,000 median household
income were more likely to be tested with OncoDX than
patients of other races, lower levels of education, or lower
incomes (p\ 0.001; Table 1).
US geographic location (geographic regions defined by
NCDB), also revealed significant impact on test utilization
(New England used as a referent in calculating odds ratio
for being tested with OncoDX, Table 1).
The NCCN-defined intermediate-risk guidelines valid at
the time of the study (ER?/lymph node-negative/[1.0 cm
tumors) were followed in 58.1 % of tested patients; 16.4 %
tests were performed in patients with CN1 disease. The
majority of tests were performed on patients with T1c
tumors, followed by T1b tumors (Table 2).
Interestingly, 24 % of ordered tests did not follow the
guidelines applicable at the time of the study: 2.9 % of
tested patients were HER2-positive; 3.2 % had T1a tumors;
16.4 % had positive lymph nodes, and 1.5 % had advanced
III&IV cancer stage (Table 2).
Low-risk RS had 92.2 % negative predictive value for
no adjuvant chemotherapy administration. Intermediate-
risk RS had 40.1 % positive predictive value and high-risk
RS had 81.2 % positive predictive value for adjuvant
chemotherapy administration (Table 3).
Comparison of commercial OncoDX cut-off values for
low-, intermediate-, and high-risk RS (0–17, 18–30, and
31–100, respectively) with the new TAILORx trial-de-
fined cut-off values (0–10, 11–25, and 26–100, respec-









Low-risk  score Intermediate-risk score High-risk score
Age distribuon (%) for low, intermediate and high-risk 
Oncotype DX recurrence scores 
<40 yr 41-50 yr 51-60 yr 61-70 yr >70 yr
Fig. 1 Percent of breast cancer patients per age group was similar for
low-, intermediate-, and high-risk score in patients 41–70 years old,
but there was an increasing trend towards high-risk score in patients
younger than 40 and older than 70 years of age. While this was
expected in younger patients, it was unexpected in elderly patients
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tested fell into the low-risk RS (0–17) with commercial
OncoDX cut-off values (56.1 %), while the majority of
patients (61.3 %) with TAILORx trial-defined values fell
into the intermediate-risk RS (11–25). Chemotherapy for
high-risk OncoDX RS was not administered in almost
20 % of patients (26 % for TAILORx values) and was
administered to 7.7 % of patients with low-risk RS
(5.3 % for TAILORx values).
Vital status was known in 62.2 % of cohort’s patients;
677/46245 (1.5 %) patients were expired at the end of
3-year study period (Table 4). This statistic represents
overall mortality since NCDB does not record cancer-re-
lated mortality.
RS was a significant predictor of vital status in both
commercial and TAILORx trial-defined cut-off values
(p\ 0.001; Table 4): Patients with intermediate- and high-
risk RS were 1.37–2.76 times more likely to die, respec-
tively, than patients with low-risk RS (95 % CI 1.15–1.62
and 2.26–3.37, respectively) (Table 4) for commercial test
cut-off values.
Table 1 Race and socioeconomic characteristics of a 21-gene recurrence score assay for breast cancer (Oncotype DX) in patients tested
compared to patients eligible for testing (ER-positive, lymph node-negative, HER2-negative patients with tumor size between 0.6 cm and 5 cm)




p value* Odds ratio 95 % CI
Race 174,079 63,392
White 151,560 55,712 (36.8 %) \0.001 Referent
Black 13,958 4653 (33.3 %) \0.001 0.860 0.829–0.892
Other 6945 2461 (35.4 %) 0.025 0.944 0.898–0.993
Unknown 1616 566 (35.0 %) 0.150 0.927 0.837–1.028
Median income quartiles 2008–2012 172,730 62,948
[$63000 66,219 25,913 (39.1 %) \0.001 Referent
\$38000 23,096 7450 (32.3 %) \0.001 0.741 0.718–0.764
$38000–$47999 36,569 12,564 (34.4 %) \0.001 0.814 0.793–0.836
$48000–$62999 46,846 17,021 (36.3 %) \0.001 0.888 0.866–.910
Percent no high school degree 2008–2012 172,792 62,978
\7 % 52,617 20,978 (39.9 %) \0.001 Referent
C21 % 22,475 6857 (30.5 %) \0.001 0.662 0.640–0.685
13–20.9 % 39,273 13,325 (33.9 %) \0.001 0.775 0.754–0.796
7–12.9 % 58,427 21,818 (37.3 %) \0.001 0.899 0.877–0.921
US geographic location 174,079 63,392
New England (CT, MA, ME, NH, RI, VT) 10,652 4013 (37.7 %) \0.001 Referent
Middle Atlantic (NJ, NY, PA) 26,294 11,810 (44.9 %) \0.001 1.349 1.288–1.413
South Atlantic (DC, DE, FL, GA, MD, NC, SC, VA, WV) 38,319 13,858 (36.2 %) 0.004 0.937 0.897–0.980
East North Central (IL, IN, MI, OH, WI) 30,617 12,298 (40.2 %) \0.001 1.111 1.061–1.162
East South Central (AL, KY, MS, TN) 10,010 3308 (33.0 %) \0.001 0.817 0.771–0.865
West North Central (IA, KS, MN, MO, ND, NE, SD) 13,344 5218 (39.1 %) 0.024 1.062 1.008–1.119
West South Central (AR, LA, OK, TX) 12,384 3065 (24.7 %) \0.001 0.544 0.514–0.576
Mountain (AZ, CO, ID, MT, NM, NV, UT, WY) 9110 3424 (37.6 %) 0.898 0.996 0.940–1.055
Pacific (AK, CA, HI, OR, WA) 23,349 6398 (27.4 %) \0.001 0.624 0.595–0.656
Urban vs rural 169,207 61,748
Urban 166,495 60,748 (36.5 %) Referent
Rural 2712 1000 (36.9 %) 0.678 1.017 0.940–1.100
* Patients of Caucasian race, from regions with\7 % having no high school education, and[$63,000 median household income were more
likely to be tested with Oncotype DX test than patients of other races, education, or income (p\ 0.001). Urban versus rural location did not have
a significant impact on Oncotype DX test utilization
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Table 2 Clinicopathologic characteristics of invasive breast carcinomas tested with a 21-gene recurrence score assay for breast cancer (On-
cotype DX)







Total for all scores
0–100
# and % of analyzed patients per score 41,682 (56.1 %) 24,965 (33.6 %) 7687 (10.3 %) 74,334* (100 %)
Age
Median (interquartile range) year 59.0 (51-59) 59.0 (51-66) 59.0 (51–67) 59.0 (51–66)
Mean (year) ± SD 58.91 ± 10.42 58.59 ± 10.63 58.89 ± 11.41 58.8 ± 10.6
Comorbidities # and % per score
0 35,649 (85.5 %) 21,407 (85.7 %) 6484 (84.4 %) 63,540 (85.5 %)
1 5118 (12.3 %) 3.063 (12.3 %) 1005 (13.1 %) 9186 (12.4 %)
C2 915 (2.2 %) 495 (2.0 %) 198 (2.6 %) 1608 (2.1 %)
Tumor size (greatest dimension)
Median (interquartile range) (cm) 1.5 (1.0–2.0) 1.5 (1.1–2.1) 1.7 (1.2–2.5) 1.5 (1.1–2.1)
Mean (cm) 2.4 ± 8.6 2.4 ± 8.1 2.67 ± 8.4 2.45 ± 8.4
Tumor distribution—# and % per score
0.1–0.5 cm 1424 (3.4 %) 712 (2.9 %) 238 (3.1 %) 2374 (3.2 %)
0.6–1.0 cm 9,223 (22.1 %) 5,217 (20.9 %) 1184 (15.4 %) 15,624 (21.0 %)
1.1–2.0 cm 21,113 (50.7 %) 12,620 (50.6 %) 3518 (45.8 %) 37,251 (50.2 %)
2.1–3.0 cm 6898 (16.6 %) 4480 (18.0 %) 1843 (24 %) 13,221 (17.8 %)
3.1–4.0 cm 1664 (4.0 %) 1091 (4.4 %) 564 (7.3 %) 3319 (4.5 %)
4.1–5.0 cm 595 (1.4 %) 403 (1.6 %) 196 (2.6 %) 1194 (1.6 %)
C5.1 cm 656 (1.6 %) 384 (1.5 %) 123 (1.6 %) 1163 (1.6 %)
Unknown 67 (0.2 %) 39 (0.2 %) 13 (0.2 %) 119 (0.2 %)
Histologic grade of tumor—# and % per score
Low 14,013 (33.6 %) 5473 (21.9 %) 351 (4.6 %) 19,837 (26.7 %)
Intermediate 22,200 (53.3 %) 13,537 (54.2 %) 2572 (33.5 %) 38,309 (51.5 %)
High 3355 (8 %) 4826 (19.3 %) 4,479 (58.3 %) 12,660 (17 %)
Unknown 2114 (5.1 %) 1,129 (4.5 %) 285 (3.7 %) 3528 (4.7 %)
Number of positive lymph nodes # and %
per score
Total # = 72,568
0 33,615 (82.5 %) 20,332 (83.4 %) 6430 (86.4 %) 60,377 (81.2 %)
1 5258 (12.9 %) 2946 (12.1 %) 709 (9.5 %) 8913 (12 %)
2–3 1597 (3.9 %) 912 (3.7 %) 217 (2.9 %) 2726 (3.7 %)
C4 287 (0.7 %) 175 (0.7 %) 90 (1.2 %) 552 (0.7 %)
Cancer stage # and % per score Total # = 74,191
I 28,742 (69.1 %) 17,000 (68.2 %) 4569 (59.7 %) 50,311 (67.8 %)
II 12,078 (29.0 %) 7453 (29.9 %) 2871 (37.5 %) 22,402 (30.21 %)
III 519 (1.2 %) 315 (1.3 %) 131 (1.7 %) 965 (1.3 %)
IV 47 (0.1 %) 34 (0.1 %) 33 (0.4 %) 114 (0.2 %)
Unknown 224 (0.5 %) 121 (0.5 %) 54 (0.7 %) 399 (0.5 %)
Estrogen receptor expression—# and % per score
Negative 145 (0.3 %) 149 (0.6 %) 614 (8 %) 908 (1.2 %)
Positive 41,445 (99.4 % 24,773 (99.2 %) 7040 (91.6 %) 73,258 (98.6 %)
Borderline 2 (\ 0.01 %) 1 (\ 0.01 %) 14 (0.2 %) 17 (\ 0.01)
Unknown 90 (0.2 %) 42 (0.2 %) 19 (0.2 %) 151 (0.2 %)
Progesterone receptor expression—# and % per score
Negative 1578 (3.8 %) 3528 (14.2 %) 3126 (40.7 %) 8242 (11.1 %)
Positive 39,997 (95.9 %) 21,337 (85.5 %) 4508 (58.6 %) 65,822 (88.5 %)
Borderline 20 (\ 0.01 %) 38 (0.2 %) 26 (0.3 %) 84 (0.1 %)
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Table 2 continued







Total for all scores
0–100
Unknown 107 (0.3 %) 52 (0.2 %) 27 (0.4 %) 186 (0.3 %)
HER2 expression—# and % per score
Negative 39,686 (95.2 %) 23,304 (93.3 %) 6415 (83.5 %) 69,405 (93.4 %)
Positive 573 (1.4 %) 647 (2.6 %) 916 (11.9 %) 2,136 (2.9 %)
Borderline 601 (1.4 %) 536 (2.1 %) 210 (2.7 %) 1347 (1.8 %)
Unknown 822 (2 %) 478 (1.9 %) 146 (1.9 %) 1446 (1.9 %)
* From 91,651 patients that had Oncotype DX test performed from 2010 to 2012, 74,334 patients (81.1 %) had known Oncotype DX test score
recorded as a numerical value (0–100) and were analyzed. 74,344 is the total number of patients, if different, it is stated in the column ‘‘total for
all scores 0–100’’
Table 3 A 21-gene recurrence score breast cancer assay (Oncotype DX) score and chemotherapy administration
Oncotype DX score Chemotherapy
No Yes Unknown Total for chemotherapy values
Low-risk recurrence score (0–17) 38,057 (91.3 %) 3218 (7.7 %) 407 (1 %) 41,682 (100 %)
Intermediate-risk recurrence score (18–30) 14,827 (59.4 %) 9942 (38.8 %) 196 (0.8 %) 24,965 (100 %)
High-risk recurrence score (31–100) 1430 (18.6 %) 6214 (80.8 %) 43 (0.6 %) 7687 (100 %)
Total for all risk recurrence score values 54,314 (73.1 %) 19,374 (26.1 %) 646 (0.9 %) 74,334 (100 %)
Upon obtaining of the Oncotype DX recurrence risk score results, 73,688/74,334 (99.1 %) of patients had known chemotherapy administration
results
Table 4 Chemotherapy administration and vital status of the patients
with invasive breast carcinoma tested with a 21-gene recurrence score
assay for breast cancer (Oncotype DX): National Cancer Data Base
analysis from 2010 to 2012 comparing commercial Oncotype Dx cut-
off values [2] to the new TAILORx trial-defined cut-off values [8] for
low-, intermediate-, and high-risk recurrence scores













# and % of analyzed patients
per score; total = 74,334*
41,682 (56.1 %) 24,965 (33.6 %) 7687 (10.3 %) 15,887 (21.4 %) 45,549 (61.3 %) 12,898 (17.4 %)
Chemotherapy (# and % of analyzed patients per score; total 5 74,334)
Chemotherapy not received 38,057 (91.3 %) 14,827 (59.4 %) 1430 (18.6 %) 14,888 (93.7 %) 36,073 (79.2 %) 3353 (26 %)
Chemotherapy received 3218 (7.7 %) 9942 (39.8 %) 6214 (80.8 %) 844 (5.3 %) 9069 (19.9 %) 9461 (73.4 %)
Chemotherapy unknown 407 (1 %) 196 (0.8 %) 43 (0.6 %) 155 (1 %) 407 (0.9 %) 84 (0.7 %)
Vital status—# and % per score; total 5 46,245
Dead 280 (1.1 %) 246 (1.5 %) 151 (3 %) 113 (1.2 %) 349 (1.2 %) 215 (2.6 %)
Alive 24,813 (98.9 %) 15,912 (98.5 %) 4843 (97 %) 9056 (98.8 %) 28,298 (98.8 %) 8214 (97.4 %)
* From 91,651 patients that had Oncotype DX test performed from 2010 to 2012, 74,334 patients (81.1 %) had known Oncotype DX test score
recorded as a numerical value (0–100) and were analyzed here. 677/46,245 patients died in this study period (1.5 % overall mortality)
Patients with intermediate- and high-risk recurrence score were 1.37–2.76 times more likely to die, respectively, than patients with low-risk
recurrence score (95 % CI 1.15–1.62 and 2.26–3.37, respectively) for commercial test cut-off values. With TAILORx cut-off values, patients
with high-risk recurrence score were 2.1 times more likely to die than patients with low-risk recurrence score (95 % CI 1.66–2.63), but there was
no significant difference between low-risk recurrence score and intermediate-risk recurrence score
432 Breast Cancer Res Treat (2016) 157:427–435
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Discussion
To our knowledge, this is the first study that describes
utilization and impact of 21-gene recurrence score assay
for breast cancer (OncoDX) in clinical practices across the
entire United States.
This study revealed that there were significant racial and
socioeconomic disparities in test utilization: patients of
Caucasian race, from regions with \7 % having no high
school education, and with [$63,000 median household
income were more likely to be tested with OncoDX test
than patients of other races, lower levels of education, or
lower incomes. Racial disparity regarding OncoDX uti-
lization similar to our data was also observed by Roberts
et al. in 1468 breast cancer patients from the phase III
Carolina Breast Cancer Study [18], and by Lund et al. [21]
in 2186 breast cancer patients from tumor registries in three
Atlanta area hospitals. In both studies, breast cancer
patients of black race were less likely to undergo OncoDX
testing than Caucasian patients. However, the racial dis-
parity was not observed in Roberts’ study [18] if the test
utilization was measured only in lymph node-negative
patients. In addition, no disparity in test utilization was
seen regarding the level of education or income in lymph
node-negative patients [18], which is dissimilar to the data
seen in our study. Guth et al. published results [11] from
374 breast cancer patients in New York City revealed that
Caucasian patients and patients with higher income were
more likely to be tested with OncoDX, similar to the data
in our study. That study also showed that type of facility in
which patients were treated also influenced the utilization
of OncoDX assay, such as treatment in a tertiary center,
findings consistent with our study (data not shown).
US geographic location showed a significant impact on
OncoDX test utilization in our study: patients from Middle
Atlantic location and West North Central location were 35
and 6 %, respectively, more likely to be tested with OncoDX
than patients from New England. Patients from West South
Central, Pacific, East South Central, and South Atlantic were
46 to 7 % less likely to be tested with OncoDX, while there
was no difference in test utilization for patients living in
Mountain geographic locations when compared to the
patients from New England. To our knowledge, we are the
first to describe US geographic location differences in
OncoDX test ordering. Reasons for these observed differ-
ences will be explored in future studies.
Practices used for ordering of the OncoDX test were not
optimally followed as per the NCCN guidelines applicable
at the time of the study [22], with 24 % of tests ordered in a
non-guideline-concordant fashion, such as HER2-positive
cancers, T1a tumors, lymph node-positive, and stage
III&IV cancers. Several other studies [18, 23, 24] revealed
non-guideline-concordant ordering of the test similar to the
results in our study. The test was ordered in guideline-
concordant fashion when the test was paid for by CMS [11,
16], or when the test was being prospectively validated for
chemotherapy decision impact or economic impact [25,
26].
The impact of the OncoDX test results on adjuvant
chemotherapy use was reasonable for low- and high-risk
RS (7.7 % negative predictive value and 80.8 % positive
predictive value, respectively), but was far from satisfac-
tory in the intermediate-risk score group (40.1 % positive
predictive value for chemotherapy administration—
Table 3). The impact of the OncoDX test results on adju-
vant chemotherapy use was improved for low- and high-
risk scores when our analysis was performed on patients on
whom the test was performed in a guideline-concordant
fashion for the 2010–2012 study time period (ER-positive,
lymph node-negative, HER2-negative, with tumor size
between 0.6 and 5 cm). The latter analysis revealed a
4.6 % negative predictive value for low-risk score (1306/
28,582 patients) and 88.6 % positive predictive value for
high-risk score (3850/4343 patients). The impact was still
far from predictive in the intermediate-risk score group
(42.4 % positive predictive value for chemotherapy
administration, 6655/15,685).
The predictive value of OncoDX test results for
chemotherapy administration benefits led to the
endorsement of this test in the newest version (1.2016) of
the NCCN guidelines [6] which notes the test to be
superior to other available molecular tests. Similarly,
recently published ASCO Clinical Practice Guideline for
use of biomarkers to guide clinical decisions on adjuvant
systemic therapy for women with early-stage invasive
breast cancer [7] found OncoDX test to be evidence
based, with high evidence quality and strong strength of
recommendation to guide decisions on the need for
adjuvant chemotherapy in node-negative patients. Our
NCDB data analysis revealed that 7.7 % of patients in
the low-risk OncoDX RS category received chemother-
apy. Conversely, almost 20 % of patients with high-risk
OncoDX RS category did not receive chemotherapy. The
impact of a high-risk RS results on chemotherapy
administration in our study population was similar to
results obtained in a study of prospective evaluation of
OncoDX for breast cancer decision making in Ontario
[25]. In the study from Ontario, 81 % of patients that
were recommended to receive chemotherapy based on
their OncoDX risk RS, received chemotherapy, however,
only 2 % of patients with low-risk RS received
chemotherapy. So far, no clear evidence-based guideli-
nes have been established for chemotherapy adminis-
tration for patients with intermediate-risk RS.
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Availability of the final results of the TAILORx trial in
2020 will hopefully give more clarity to definitive evi-
dence-based guidelines for all 21-gene recurrence score
breast cancer assay test results including intermediate-risk
scores. Requesting an expensive test, obtaining an inter-
mediate-risk score result, and then not having clear
guidelines for treatment recommendations is an expensive
process, which appears to be leading to non-actionable
information. Going forward, as a health care financial
policy, this is especially concerning since up to 2/3 of the
tested patients may fall into this intermediate-risk group. It
is imperative that health care providers continually revisit
guidelines and treatment recommendations and address
appropriateness of intervention and cost in order to expend
our resources prudently.
The TAILORx trial interim report findings [8] noted
prospective validation of OncoDX 21-gene RS assay for
breast cancer although notably introduced an entirely dif-
ferent range of cut-off values for the low-, intermediate-,
and high-risk RS from the traditional commercial test
values. Interestingly, the TAILORx trial revealed that the
overall survival in patients with really low-risk RS was
98 % at 5 years of follow-up; our NCDB data analysis
revealed similar overall survival for all groups at 98.5 %,
however, with only 3 years of follow-up. Noteworthy, our
data analysis revealed that high-risk RS was a significant
predictor of worse overall survival in comparison with a
low-risk RS, suggesting that the test, if appropriately
interpreted and applied, may have not only have prognostic
relevance for recurrence but also for overall survival.
Limitations as well as strengths of our study both lie in the
methodology of data collection by the NCDB. The NCDB
does not record recurrences of breast cancer at a distant or
locoregional site, and does not record breast cancer-specific
mortality, making follow-up studies of these patients for
population-based validation of OncoDX 10-year RS results
impossible. Another limitation includes the lack of record on
the type of comorbidities encountered, which could poten-
tially influence chemotherapy administration decisions. In
addition, the NCDB neither identify the type of physician
who orders OncoDX test (surgeon vs oncologist), nor can
identify the balance between the patient and the clinician in
decision making for or against chemotherapy use once the
OncoDX test results are known, both of which greatly
influence chemotherapy administration decisions. We also
acknowledge the accepted NCDB process of recording data
which allows inclusion of records that are only partially
complete. The OncoDX test was performed in 91,651
patients from 2010 to 2012, but the test results were
unknown in 5242 (5.7 %) patients, or recorded only as low-,
intermediate-, and high-risk RS, without associated numer-
ical values in 12,075 (13.2 %) patients, rendering almost
20 % of results unusable for some parts of our study.
A significant strength of this study is that data are
derived from a very large number of patients across the
United States in a database that includes more than 1500
CoC accredited facilities and approximately 70 % of all
newly diagnosed malignancies.
Conclusions
This NCDB analysis reveals that race, socioeconomic
status, and US geographic location impact utilization of the
OncoDX test result in clinical practices across the United
States. These data also reveal that at least 10 % of tests are
ordered in a non-guideline-concordant fashion (up to 24 %
if guidelines applicable during the time of the study are
applied). Compliance with treatment recommendations
based on OncoDX test results is reasonable for low- and
high-risk RS. The impact of an intermediate-risk RS
resulting in only a 40.1 % positive predictive value for
chemotherapy administration suggests the need for clearer,
evidence-based guidelines.
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